GlassScriptPhysician profile
Otis Gowdy
NPI 1992782544
$11,558.44
in general payments reported to CMS, 2019-2025
20 companies · $535 in 2025
The $535 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $59.54 · 2021: $1,382 · 2022: $4,599 · 2023: $4,134 · 2024: $495 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,400 · Food and Beverage: $1,884 · Travel and Lodging: $853 · Education: $26.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,400.00 |
| Food and Beverage | $1,884.49 |
| Travel and Lodging | $853.47 |
| Education | $26.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $8,696.92 | 2021-2023 | Korsuva |
| Astrazeneca Pharmaceuticals LP | $689.51 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $568.98 | 2022-2025 | |
| Akebia Therapeutics INC | $444.25 | 2019-2025 | Vafseo, Auryxia |
| Aurinia Pharma U.S., INC. | $316.69 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $253.99 | 2024-2025 | |
| Vifor Pharma, INC. | $147.34 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $63.46 | 2020-2025 | Jynarque |
| Lilly USA, LLC | $58.47 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $44.11 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $40.86 | 2021 | |
| Bard Peripheral Vascular, INC. | $37.59 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.95 | 2025 | Jardiance |
| Amgen INC. | $31.48 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.78 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23.47 | 2019 | |
| Calliditas Therapeutics US INC. | $22.71 | 2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $21.09 | 2023 | Terlivaz |
| Travere Therapeutics, INC. | $19.48 | 2024-2025 | Filspari |
| Horizon Therapeutics Plc | $19.31 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Otis Gowdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.